SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Want to cut your energy bills? Here’s how five experts are doing it 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
DURHAM, N.C., March 09, 2016 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that Linda M. Richardson, Chief Commercial Officer of Chimerix, will present at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016 at 2:35 p.m. ET at the Loews Miami Beach Hotel in Miami, FL.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals to address unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir, a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Jesse Baumgartner Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
